John Cumming

Direktor/Vorstandsmitglied bei T2 BIOSYSTEMS, INC.

Vermögen: 142 $ am 30.04.2024

78 Jahre

100 Beziehungen

Health Technology

Consumer Services

Commercial Services

Aktive Beziehungen

Name	Geschlecht	Alter	Unternehmensverbindungen	Zusammenarbeit
John Sperzel	M	60	T2 BIOSYSTEMS, INC.	4 Jahre
Stephen MacMillan	M	60	HOLOGIC, INC.	11 Jahre
Eugene H. Vetter	M	-	Transmed7 LLC Transmed7 LLC Medical SpecialtiesHealth Technology Transmed7 LLC is a medical and technology-based organization that focuses on developing innovative, minimally-invasive medical devices for doctors and their patients. The private company is based in Phoenix, AZ. The company's portfolio of next-generation platform devices is expected to be market leaders in oncology, regenerative medicine, and cardiovascular disease. Transmed7's business plan and structure enable these new transformational technologies to move from rapid development through commercial manufacturing and market deployment. The company's transformational forward-coring, zero5 biopsy devices improve patient care with broad applications to breast, soft tissue, endoscopy, laparoscopy, robotics, vascular, bone marrow, and more. The company was founded in 2010 by Eugene H. Vetter, James W. Vetter. Eugene H. Vetter has been the CEO since 2010.	14 Jahre
Matthew McKillip	M	-	T2 BIOSYSTEMS, INC.	-
Sally Crawford	F	70	HOLOGIC, INC.	17 Jahre
David MacKeen	M	-	Bentley University	17 Jahre
James W. Vetter	M	-	Transmed7 LLC Transmed7 LLC Medical SpecialtiesHealth Technology Transmed7 LLC is a medical and technology-based organization that focuses on developing innovative, minimally-invasive medical devices for doctors and their patients. The private company is based in Phoenix, AZ. The company's portfolio of next-generation platform devices is expected to be market leaders in oncology, regenerative medicine, and cardiovascular disease. Transmed7's business plan and structure enable these new transformational technologies to move from rapid development through commercial manufacturing and market deployment. The company's transformational forward-coring, zero5 biopsy devices improve patient care with broad applications to breast, soft tissue, endoscopy, laparoscopy, robotics, vascular, bone marrow, and more. The company was founded in 2010 by Eugene H. Vetter, James W. Vetter. Eugene H. Vetter has been the CEO since 2010.	14 Jahre
Ninfa Saunders	M	72	T2 BIOSYSTEMS, INC.	4 Jahre
Scott Garrett	M	73	HOLOGIC, INC.	11 Jahre
Robin Toft	F	63	T2 BIOSYSTEMS, INC.	4 Jahre
Michael Gibbs	M	53	T2 BIOSYSTEMS, INC.	10 Jahre
John Sprague	M	65	T2 BIOSYSTEMS, INC.	6 Jahre
Seymour Liebman	M	74	T2 BIOSYSTEMS, INC.	8 Jahre
Christiana Stamoulis	F	53	HOLOGIC, INC.	13 Jahre
Laura Adams	F	67	T2 BIOSYSTEMS, INC.	3 Jahre
Karleen Oberton	F	54	HOLOGIC, INC.	18 Jahre
David Elsbree	M	76	T2 BIOSYSTEMS, INC.	10 Jahre
Kelley Morgan	F	-	T2 BIOSYSTEMS, INC.	10 Jahre
Patricia Flynn	F	74	Bentley University	48 Jahre
William Pappas	M	-	Bentley University	-
Monica Berthelot	F	-	HOLOGIC, INC.	12 Jahre
Roger Smith	M	59	T2 BIOSYSTEMS, INC.	10 Jahre
Richard Gnospelius	M	-	Bentley University	-
Jeff Coyne	M	-	Transmed7 LLC Transmed7 LLC Medical SpecialtiesHealth Technology Transmed7 LLC is a medical and technology-based organization that focuses on developing innovative, minimally-invasive medical devices for doctors and their patients. The private company is based in Phoenix, AZ. The company's portfolio of next-generation platform devices is expected to be market leaders in oncology, regenerative medicine, and cardiovascular disease. Transmed7's business plan and structure enable these new transformational technologies to move from rapid development through commercial manufacturing and market deployment. The company's transformational forward-coring, zero5 biopsy devices improve patient care with broad applications to breast, soft tissue, endoscopy, laparoscopy, robotics, vascular, bone marrow, and more. The company was founded in 2010 by Eugene H. Vetter, James W. Vetter. Eugene H. Vetter has been the CEO since 2010.	-
Gordon McLenithan	M	-	Bentley University	-
Darryl Poole	M	-	Bentley University	-
Frank Kelly	M	-	Bentley University	-
Deborah Millin	F	-	Bentley University	-
Nickolas Stavropoulos	M	66	Bentley University	-
Brett Giffin	M	66	T2 BIOSYSTEMS, INC.	3 Jahre
Brian Zino	M	72	Bentley University	13 Jahre
George W. Carmany	M	84	Bentley University	-
Patrick J. Gnazzo	M	77	Bentley University	-
Debora Spar	M	60	Bentley University	-
Andrew J. Hajducky	M	70	Bentley University	-
Michael J. Cyrus	M	68	Transmed7 LLC Transmed7 LLC Medical SpecialtiesHealth Technology Transmed7 LLC is a medical and technology-based organization that focuses on developing innovative, minimally-invasive medical devices for doctors and their patients. The private company is based in Phoenix, AZ. The company's portfolio of next-generation platform devices is expected to be market leaders in oncology, regenerative medicine, and cardiovascular disease. Transmed7's business plan and structure enable these new transformational technologies to move from rapid development through commercial manufacturing and market deployment. The company's transformational forward-coring, zero5 biopsy devices improve patient care with broad applications to breast, soft tissue, endoscopy, laparoscopy, robotics, vascular, bone marrow, and more. The company was founded in 2010 by Eugene H. Vetter, James W. Vetter. Eugene H. Vetter has been the CEO since 2010.	6 Jahre
John Poduska	M	86	Bentley University	-
Dan A. Keshian	M	-	Bentley University	-
Alan P. Cleveland	M	-	Bentley University	-
Robert Badavas	M	71	Bentley University	19 Jahre
Mark B. Skaletsky	M	75	Bentley University	-
Robert R. Anderson	M	86	Bentley University	-
Raul Claure	M	52	Bentley University	-
Tracy A. Sykes	F	-	Transmed7 LLC Transmed7 LLC Medical SpecialtiesHealth Technology Transmed7 LLC is a medical and technology-based organization that focuses on developing innovative, minimally-invasive medical devices for doctors and their patients. The private company is based in Phoenix, AZ. The company's portfolio of next-generation platform devices is expected to be market leaders in oncology, regenerative medicine, and cardiovascular disease. Transmed7's business plan and structure enable these new transformational technologies to move from rapid development through commercial manufacturing and market deployment. The company's transformational forward-coring, zero5 biopsy devices improve patient care with broad applications to breast, soft tissue, endoscopy, laparoscopy, robotics, vascular, bone marrow, and more. The company was founded in 2010 by Eugene H. Vetter, James W. Vetter. Eugene H. Vetter has been the CEO since 2010.	-
William Freda	M	71	Bentley University	-
Elizabeth Rainoff	F	-	Bentley University	-

Mehr sehen

Beziehungs-Chart

Beziehungen zu mehreren Unternehmen

Ehemalige Beziehungen

Name	Geschlecht	Alter	Unternehmensverbindungen	Zusammenarbeit
S. David Ellenbogen	M	-	HOLOGIC, INC.	24 Jahre
Robert Cascella	M	69	HOLOGIC, INC.	10 Jahre
John McDonough	M	65	T2 BIOSYSTEMS, INC.	14 Jahre
Elaine S. Ullian	F	76	HOLOGIC, INC.	19 Jahre
David LaVance	M	70	HOLOGIC, INC.	-
Michael Cima	M	64	T2 BIOSYSTEMS, INC.	14 Jahre
Mark Joseph Casey	M	60	HOLOGIC, INC.	7 Jahre
Wayne L. Wilson	M	75	HOLOGIC, INC.	9 Jahre
Michael J. Watts	M	-	HOLOGIC, INC.	-
Adrian Jones	M	59	T2 BIOSYSTEMS, INC.	4 Jahre
Thomas Carella	M	49	T2 BIOSYSTEMS, INC.	3 Jahre
Darlene Deptula-Hicks	F	66	T2 BIOSYSTEMS, INC.	1 Jahre
Alan Crane	M	60	T2 BIOSYSTEMS, INC.	8 Jahre
David Harding	M	58	T2 BIOSYSTEMS, INC. HOLOGIC, INC.	2 Jahre
Robert Langer	M	75	T2 BIOSYSTEMS, INC.	8 Jahre
Stanley Lapidus	M	75	T2 BIOSYSTEMS, INC.	12 Jahre
Josh Bilenker	M	52	T2 BIOSYSTEMS, INC.	6 Jahre
Thierry Bernard	M	60	T2 BIOSYSTEMS, INC.	3 Jahre
Nancy L. Leaming	F	76	HOLOGIC, INC.	14 Jahre
Jody Campbell	M	-	HOLOGIC, INC.	17 Jahre
Steven Williamson	M	51	HOLOGIC, INC.	5 Jahre
Bret Christensen	M	53	HOLOGIC, INC.	10 Jahre
Jason Cervi	M	45	HOLOGIC, INC.	1 Jahre
Anthony Pare	M	62	T2 BIOSYSTEMS, INC.	-
Alec Barclay	M	43	T2 BIOSYSTEMS, INC.	6 Jahre
Constance Bridges	F	-	HOLOGIC, INC.	6 Jahre
Joanne Spadoro	M	65	T2 BIOSYSTEMS, INC.	2 Jahre
Joel Centeno	M	-	HOLOGIC, INC.	5 Jahre
Stacy Feld	F	51	T2 BIOSYSTEMS, INC.	4 Jahre
Shawn Lynch	M	-	T2 BIOSYSTEMS, INC.	1 Jahre
Sharon L. Smith	F	-	HOLOGIC, INC.	12 Jahre
Mark D. Myslinski	M	67	HOLOGIC, INC.	-
Richard Golin	M	71	HOLOGIC, INC.	1 Jahre
Michael A. Pfaller	M	73	T2 BIOSYSTEMS, INC.	4 Jahre
Robb Paul Hesley	M	61	HOLOGIC, INC.	4 Jahre
Carl Hull	M	66	HOLOGIC, INC.	1 Jahre
John Bellano	M	56	HOLOGIC, INC.	1 Jahre
Jeffrey Hawkins	M	46	HOLOGIC, INC.	1 Jahre
Peter C. Kershaw	M	70	HOLOGIC, INC.	3 Jahre
Arthur G. Lerner	M	83	HOLOGIC, INC.	2 Jahre
Jorge Garces	M	52	HOLOGIC, INC.	4 Jahre
Laurie L. Fajardo	M	68	HOLOGIC, INC.	1 Jahre
Howard Doran	M	63	HOLOGIC, INC.	3 Jahre
Michael Levitz	M	50	HOLOGIC, INC.	2 Jahre
William A. Peck	M	91	HOLOGIC, INC.	15 Jahre
Gregory Hamilton	M	54	HOLOGIC, INC.	1 Jahre
Patrick Sullivan	M	72	HOLOGIC, INC.	1 Jahre
Daniel Levangie	M	73	HOLOGIC, INC.	1 Jahre
C. William McDaniel	M	82	HOLOGIC, INC.	1 Jahre
Maurice L. Castonguay	M	72	T2 BIOSYSTEMS, INC.	1 Jahre
Mark Duerst	M	-	HOLOGIC, INC.	22 Jahre
Peter K. Soltani	M	63	HOLOGIC, INC.	-
Steven L. Nakashige	M	-	HOLOGIC, INC.	8 Jahre
Ed Hutchinson	M	-	HOLOGIC, INC.	5 Jahre

Statistik

Land	Beziehungen	% des Gesamten
Vereinigte Staaten	100	100,00%

Alter der Beziehungen

Aktive

Vergangene

Herr

Frau

Aufsichtsräte

Führungskräfte

Ursprung der Beziehungen

Börse
Insiders
John Cumming
Persönliches Netzwerk